Friday, August 26, 2016
On January 30, 2015, US President Obama launched the Precision Medicine Initiative and precision medicine has become the spotlight of global healthcare industry. Meanwhile, Chinese President Xi Jinping appointed the NHFPC and the MOST to establish the National Precision Medicine Strategic Expert Committee. Chinese Precision Medicine Plan has been included in the 13th FYP for national major science & technology specific projects and precision medicine has become China’s national strategy. Currently, global precision medicine market values about $60 billion and the growth rate is estimated up to 15% from 2015 to 2020, which equals almost 3-4 times of the entire pharmaceutical industry. Stimulated by favorable policies and funding environment, and with the rapid technology advancements of NGS, gene editing, biochip, IVD, liquid biopsy, anti-body drugs R&D, cell immunotherapy, big data and inspiring research breakthroughs, precision medicine industry is embracing new development opportunities.
In such context,“World Precision Medicine (China) Summit 2016”, co-organized by SAPA,FENGLIN L&H and HEALIFEGROUP, consigned by NHFPC and MOST, and supported by Shanghai Biopharmaceutics Industry Association (SBIA), Shanghai Clinical Research Center, Shanghai Medical Innovation& Development Foundation, Shanghai Medical Instrument Trade Association, Precision Medicine Branch of China Medical Biotech Association, China Precision Medicine Technology Innovation Alliance, Shanghai Precision Medicine Innovation Alliance, China Strategic Alliance of Technology Innovation for Minimally Invasive Tumor Therapy, will be held on December 3-4, 2016 in Shanghai, China. Under the theme of “Gaining a Clearer Perspective into Innovation Trends, Technology Advancements and Cooperation Opportunities”, WPMCS2016 brings together 1,000+ senior executives from Government, academy, hospitals, big pharmas, life sciences & biotech companies, CROs, VCPEs to discuss the redhot topics such as China-US precision medicine market outlook and evolving regulatory landscape, big data, advanced technologies and investment opportunities, biobank & cohort study, cell immunotherapy, genetic testing &IVD, innovation & cooperation of antibody drugs, clinical therapy of tumor. Geographically, besides the delegates from Mainland China, a large number will be travelling from the United States, Europe, Israel, Japan, Korean, Singapore, Taiwan and many other countries and areas. WPMCS2016 offers an ideal balance of scientific sessions and networking opportunities.
WPMCS2016 Features:
1,000+senior participants from global precision medicine fraternity
500+senior representatives from big pharma/biotech/ life science/research institutions
200+ one-to-one Meetings
100+ world-class eminent speakers
50+ exhibitors
5 parallel symposiums on: Genetic Testing &IVD, Innovation &Cooperation of Antibody Drugs, Clinical Therapy of Tumor,Biobank&Cohort Study, Cell Immunotherapy
1 half-day project financing roadshow matching focusing on Gene Sequencing, Biochip, Liquid Biopsy, Anti-body Drugs and Cellular Immunotherapy
Pluspost-event US precision medicine business trip
Agenda Framework:
|
Day One 3 Dec.Morning Plenary Session: China-US Precision Medicine Market Outlook and Evolving Regulatory Landscape |
||
|
Day One 3 Dec.Afternoon Plenary Session: Big Data, Advanced Technologies andInvestment Opportunities |
||
|
Day Two 4 Dec. Morning ParallelSymposiums |
||
|
Parallel Symposium I: Genetic Testing &IVD |
Parallel Symposium II: Antibody Drugs R&D |
Parallel SymposiumIII: Clinical Therapy of Tumor |
|
Day Two 4 Dec. Afternoon Parallel Symposiums |
||
|
Parallel Symposium IV: Biobank&Cohort Study |
Parallel Symposium V: Cell Immunotherapy |
Parallel Symposium VI: Project Financing Road Show |
Part of Eminent Speakers (under Invitation)
• Government Officials&/Association Leaders:
China Food and Drug Administration (CFDA)Deputy Director,Wu Zhen
Ministry of Science and Technology PRC Director, Department of S&T for Social Development, Chen Chuanhong
National Institutes of Health (NIH) Director, Francis CollinsPh.D
FDA China Office Director, Leigh VerboisPh.D
SAPA President, Johnson&Johnson Scientific Director/Janssen Fellow, Dai WeiguoPh.D
Precision Medicine Coalition President, Edward Abrahams
• UniversityProfessors /Research/Medical Institutions’ Experts:
Chinese Academy of Science & Peking Union Medical College Vice President/ Peking University Health Science Center Director,Zhan QiminAcademician
Fudan University Vice President,Jin LiAcademician
Shanghai Cell Therapy Research Institute President, QiaoQijunPh.D
Institute of Biophysics, Chinese Academy of Sciences Researcher,Chen RunshengAcademician
Beijing National Biochip Research CenterDirector,Cheng JingAcademician
Zhongshan Hospital Fudan UniversityPresident,Fan Jia
West China Hospital, Sichuan UniversityPresident,Li Weiming
Shandong Tumor Hospital President, Yu JinmingAcademician
The Third Hospital of the Second Military Medical University Vice President, WangHongyang Academician
Tianjin Medical University Cancer Institute & HospitalPresident/ Big Data Center for Precision Medicine Director, Wang Ping
The Affiliated Hospital of Nanjing University Medical School Vice President/ Tumor Center Director, Liu Baorui
University of Texas MD Anderson Cancer Center Tenured Associate Professor, Liang Han
Mayo Clinic, Technology Assessment Group (TAG), Center for Individualized Medicine Chairman, David Smith
Ministry of Health, Xiangya Hospital Central South University, Key Laboratory of Cancer Proteomics Professor, Zhan Xianquan
Shanghai Institute of MateriaMedica, Chinese Academy of Science Vice President, GengMeiyu
Shanghai Center for Drug Discovery & Development Director,Shao Liming
Shanghai Center for Bioinformation Technology Director, Li Yixue
Institute of Biomedical Sciences Fudan UniversityProfessor,Liu Lei
TMRC/CTCTCTProfessor& Executive Director,ZengJimeng
Heibei University of Science and Technology Associate Professor,Han Chunyu
• Global Precision Medicine enterprises/VCPE Senior Executives
BGIChairman, Wang Jian Academician
Shanghai Fenglin life Healthcare Development Co.,LTDChairman, Wu Yinfei
Pfizer Global Product DevelopmentOncology, Chief Development Officer,MaceRothenberg
Eli Lilly and CompanySenior Vice President, China Drug DevelopmentKerry Blanchard
Johnson & Johnson Asia-Pacific Innovation Center, Senior Director, Xia Mingde
Amgen Vice President of Global R&D, Zhang Mingqiang
GenentechCancer ImmuneTherapies,Companion Diagnostics Group Leader,Andy Williams
Roche Innovation CenterHead of Data Science Application Services,Jan Kuentzer
LabCorpChairman & CEO,David King
Seattle GeneticsCMO & EVP,Research and Development,Jonathan Drachman
MerckVice President, Head of Translational Medicine, Robert Plenge
TevaVice President, Head of Personalized & Predictive Medicine and Big Data Analytics, Iris Grossman
RegeneronPhamarceuticals,Regeneron Laboratories &Chief Science Officer,President,George Yancopoulos
GSK, SVP Target Sciences, Lon Cardon
Macrogen, NGS Division,General Manager,Bon-Chao Kim
Jiangsu Hengrui Medicine Co, .Ltd,Vice President of Global R&D,Zhang Lianshan
Intel Healthcare and Life Sciences Division,Asia GMYu Yi
Cloud Health GenomicsPartner &President,Jin Gang
Roche Diagnostics ChinaCEO Huang Boxing
Shanghai LIDE Biotech Co., LtdChairman& CEO,Wen Yidan
Dian Diagnostics Chairman,Chen Haibin
Berry Genomics Chairman, Gao Yang
Sunland FundFounding &Executive Partner, Liu Daozhi
Sequoia CapitalPartner,Chen Penghui
Legend CapitalGM&CEO,Chen Hao
Qiming Venture PartnersManaging Partner,Liang Yingyu
BioVentureFounding Partner, Chen Jie
For more information, please visit: www.wpmcs.com.cn
Organizer Contact Person: Ms. Karen YAU& Ms. Emily WANG
Mobile: +86 18918108518& +86 13122212215
Email: karenyou@healife.com&emilywang@healife.com
